contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


promising-results-farons-bexmab-blood-cancer-study

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Atte Riikola

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

How long after the diagnosis does potential treatment begin? However, this is a very dangerous disease, and I would like to believe that treatment is aimed to start as quickly as possible, and not, for example, be postponed for months. If a patient seeks treatment at an institution involved in research collaboration, they will probably be offered such experimental treatment. Could this be a situation where the baseline TI comes from the disease being diagnosed, blood transfusions have not been given but medication has been started immediately, and thus the patient has not received blood transfusions even if there was a need, and transfusions have also been started as quickly as possible, but TI is listed when no transfusions were given before treatments? Indeed, that seems like a bit of an odd way to list it, but before we dig into the swimlanes for aza that look the same, I’m not particularly worried about this minor detail either.

It can be difficult to believe if one hasn’t seen similar shoddy reporting before and doesn’t have expertise in the field. It’s a shame that Finland doesn’t have its own Stat News. Adam would have debunked this right away. Tipping off Kauppalehti doesn’t help much.

This has become a heavy thread to read, but I checked now that many new messages had arrived, and the same rant continued here.  Well, I looked as advised, here are the swimlanes grabbed from the poster. 6/7 practically received a blood transfusion on the same day or within a couple of days of starting treatment, so the need for it could not have been caused by the treatment. The seventh one hasn’t needed many transfusions during treatment.  My interpretation: these patients had transfusions before, not marked in the picture.  If something still bothers you, a tip: it’s better to ask Kotro than to develop deep rabbit hole theories.  Thank you for your attention to a layman’s morning thoughts, while sipping coffee.

I only read the introduction. Quote: “In this review, we discuss experiences from recently reported negative azacitidine studies where it was used in combination with eprenetapoptin (APR-246), magrolimab, pevonedistat, sabatolimab, tamibarotene, and venetoclax.” Was BEX included in those tables?

As an economist, I must also add that every avoided blood transfusion (about which there is no ambiguity here) saves a lot of treatment costs and hospital days (how much does 1 cost?). In addition, the patient’s quality of life without blood transfusion(s) is certainly better than in the transfusion circus…

As a layman, I’m not quite selling my shares because of this yet. Logically, TD has changed to TI. In both cases, BEX has been involved. AZA causes the need for (even multiple) blood transfusions, so at least to me, it sounds good that these can be avoided when BEX is included in the treatment mix. It’s great that criticism and relentless challenging of data are present on the forum. Hopefully, Faron also understands that especially in this sensitive situation, there’s no room for error. If even the slightest ambiguity has arisen regarding the headline topic, Faron “must” throw a lifebuoy into the water on Monday - i.e., a clarification to the announcement. Yes, in partnership negotiations, all raw data is on the table. As I understand it, Clark’s criticism does not concern the data itself, but how it was handled when the results were announced… In my opinion, transfers have been able to be reduced quite well in any case.

So TD: transfusion-dependent  TI: transfusion-independent These are medically 2 completely different things: A) TD before treatment, which changes to TI  B) TI before treatment, during treatment TD develops which changes to TI Point A is what is generally observed. Success in it indicates that the disease itself has improved. Point B mainly indicates that as a combined effect of the disease and treatment, a temporary need for transfusions developed, which then resolved. Faron communicates that A was achieved, 57% of patients who were baseline TD became TI. In the poster, the left-hand table: baseline TD 7. TD to TI conversion 4/7 (note! It is not stated that conversion is from baseline) Swimlanes: the blue box starts when the patient enters the study. Treatment begins at the [ mark. You will notice that no one received a transfusion between study enrollment and the start of treatment. For most, the transfusion markers begin immediately after treatment. The caption states “patients who converted from TD to TI during bex+aza treatment”, no mention of baseline. Thus, 4 patients are in category B, they were most likely baseline TI. Therefore, the result 4/7 = 57% cannot be reported. I don’t know if this is pure incompetence or data spinning. Both happen.

Faron Pharmaceuticals

On Wednesday, Faron Pharmaceuticals published new positive results from the BEXMAB study to examine the efficacy of the company's precision immunotherapy treatment (bexmarilimab) for a number of malignant haematological tumors, or blood cancers. 

Translation: Original comment published in Finnish on 7/19/2023 at 6:40 am. On Wednesday, Faron Pharmaceuticals <a href="https://www.inderes.se/releases/faron-pharmaceuticals-oy-bexmab-study-update-4">published</a> new positive results from the BEXMAB study to examine the efficacy of the company's precision immunotherapy treatment (bexmarilimab) for a number of malignant haematological tumors, or blood cancers. Faron also stated that they plan to file the first Biologics License Application (BLA) to FDA in H1’25. According to the company, the data received so far in the study supports moving to clinical Phase II. This move is already included in our modeling as a very likely scenario in our estimates. So there is no need for major estimate changes, but we will review our assumptions in connection with our Q2 pre-comment. Our latest update on Faron is available <a href="https://www.inderes.se/research/faron-pharmaceuticals-bexmab-studys-good-momentum-supports-valuation">here.</a>

	2022	23e	24e
Revenue	0.0	0.0	0.0
growth-%
EBIT (adj.)	-27.4	-15.8	-3.1
EBIT-% (adj.)	-685,650.0 %	-394,522.5 %	-76,864.0 %
EPS (adj.)	-0.48	-0.25	-0.05
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Promising results from Faron's BEXMAB blood cancer study

Key Estimate Figures17.04.2023

Forum discussions